详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China West China School of Medicine, Sichuan University, Chengdu, China. [2]Sichuan Aerospace System Engineering Institute, Chengdu, China. [3]Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China. [4]Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. [5]Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. [6]Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.

出处：

DOI：

ISSN：

关键词： Hyperthyroidism Hypothyroidism Nivolumab Non-small cell lung cancer PD-1 Pembrolizumab Thyroid dysfunction

摘要：

Thyroid function abnormality (TFA) is a common immune-related adverse event (irAEs), but the association between it and the efficacy of programmed cell death protein 1 (PD-1) inhibitor in advanced non-small cell lung cancer (NSCLC) is finitely understood. We conducted a single center, retrospective study of advanced NSCLC patients who were treated with PD-1 inhibitors between 10 October 2016 and 1 April 2020. TFA was characterized as new onset subclinical hypothyroidism, overt hypothyroidism, subclinical hyperthyroidism and overt hyperthyroidism. Frequency of development of TFA-irAEs, and its relationship with overall survival (OS) and progression free survival (PFS) were evaluated. In our study, 191 patients were treated with PD-1 inhibitors. Among them, forty patients (20.9%) developed TFA, of whom 10 (5.2%) presented with subclinical hypothyroidism, 15 (7.9%) with overt hypothyroidism, 6 (3.1%) with subclinical hyperthyroidism and 9 (4.7%) with overt hyperthyroidism. Survival analysis showed that the OS (16.8 months vs. 11.1 months, p < 0.001) and PFS (10.4 months vs. 5.5 months, p < 0.001) were significantly longer in patients with TFA-irAEs than in those without TFA-irAEs. In subgroup analysis of hypothyroidism and hyperthyroidism groups, similar trends were also obtained for both OS and PFS. After adjusting for potential confounding variables, patients with TFA-irAEs had a lower mortality risk (HR 0.334, 95%CI 0.196-0.571) than those without TFA-irAEs. TFA-irAEs is associated with enhanced PD-1 inhibitor efficacy in advanced NSCLC patients and it may be a biomarker for antitumor immune response. Copyright © 2020. Published by Elsevier B.V.

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 2 区医学

小类 | 2 区药学 3 区免疫学

最新[2023]版：

大类 | 2 区

医学

小类 | 2 区免疫学 2 区药学

第一作者：

第一作者机构： [1]Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China West China School of Medicine, Sichuan University, Chengdu, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) [2]Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) [3]Choosing PD-1 Inhibitors in Oncology Setting, Left or Right?-Lessons From Value Assessment With ASCO-VF and ESMO-MCBS [4]A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004) [5]Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)(Open Access) [6]中国非小细胞肺癌免疫检查点抑制剂治疗专家共识(2019年版） [7]Single-cell profiling reveals the heterogeneity of NK cells during anti-PD-1 therapy in non-small-cell lung cancer [8]Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations [9]CheckMate 870: An Open-label Safety Study of Nivolumab in Previously Treated Patients With Non-Small Cell Lung Cancer in Asia [10]Single-cell profiling reveals the heterogeneity of NK cells during anti-PD-1 therapy in non-small-cell lung cancer